1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

ALS Data For Verdiperstat Expected In 2022

 
• By Mandy Jackson

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

A Businessperson Stopping Colorful Dominoes From Falling On Desk
Late-stage failures have stopped Biohaven from achieving success outside of its migraine pipeline • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd. wants to be a player in neurological and neuropsychiatric diseases, but the company has yet to report a clinical trial success outside of its CGRP inhibitor platform for the treatment of migraine. The most recent setback, disclosed on 27 September, is the failure of the myeloperoxidase (MPO) enzyme inhibitor verdiperstat in multiple system atrophy (MSA) to differentiate from placebo on the primary and secondary endpoints in a Phase III trial.

Analysts consistently viewed the setback as a minor event for Biohaven since the company’s valuation is largely based on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

 
• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

More from R&D

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.